Key result
Circulating microRNAs offer potential as epigenetic biomarkers for differentiating heart failure subtypes (HFrEF and HFpEF) and providing diagnostic and prognostic insights.
Why the study?
Heart failure subtypes HFpEF and HFrEF share similar clinical syndromes but differ in mortality and therapeutic response, motivating an exploration of whether distinct circulating microRNA profiles can provide diagnostic or prognostic utility.
Do circulating microRNAs have diagnostic and prognostic value in differentiating heart failure subtypes (HFrEF and HFpEF)?
Do circulating microRNAs have diagnostic and prognostic value in differentiating heart failure subtypes (HFrEF and HFpEF)?
Circulating microRNAs may serve as valuable diagnostic and prognostic biomarkers to differentiate between heart failure subtypes such as HFrEF and HFpEF.
Answers are grounded in this paper and cite their sources.
May support microRNA profiling in HF subtyping; leaves open need for prospective validation before clinical use.
Circulating microRNAs offer attractive potential as epigenetic disease biomarkers by virtue of their biological stability and ready accessibility in liquid biopsies. Numerous clinical cohort studies have revealed unique microRNA profiles in different disease settings, suggesting utility as markers with diagnostic and prognostic applications. Given the complex network of microRNA functions in modulating gene expression and post-transcriptional modifications, the circulating microRNA landscape in disease may reflect pathophysiological status, providing valuable information for delineating distinct subtypes and/or stages of complex diseases. Heart failure (HF) is an increasingly significant global health challenge, imposing major economic liability and health care burden due to high hospitalization, morbidity, and mortality rates. Although HF is defined as a syndrome characterized by symptoms and findings on physical examination, it may be further differentiated based on left ventricular ejection fraction (LVEF) and categorized as HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). The presenting clinical syndromes in HFpEF and HFrEF are similar but mortality differs, being somewhat lower in HFpEF than in HFrEF. However, while HFrEF is responsive to an array of therapies, none has been shown to improve survival in HFpEF. Herein, we review recent HF cohort studies focusing on the distinct microRNA profiles associated with HF subtypes to reveal new insights to underlying mechanisms and explore the possibility of exploiting these differences for diagnostic/prognostic applications.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) conducted a review in Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF). Circulating microRNAs was evaluated. Circulating microRNAs offer potential as epigenetic biomarkers for differentiating heart failure subtypes (HFrEF and HFpEF) and providing diagnostic and prognostic insights.
Synapse has enriched 10 related papers. Consider them for comparative context: